RT Journal
A1 Mitka M
T1 TReatment for lupus, first in 50 years, offers modest benefits, hope to patients
JF JAMA
JO JAMA
YR 2011
FD May 4
VO 305
IS 17
SP 1754
OP 1755
DO 10.1001/jama.2011.548
UL http://dx.doi.org/10.1001/jama.2011.548
AB 
Also, evidence regarding the efficacy of the new drug, belimumab (Benlysta, Human Genome Sciences), is largely confined to effects on the musculoskeletal and mucocutaneous systems. Patients with active lupus involving the kidney or central nervous system—2 sites often severely affected by the disease—were excluded from the 2 key trials examining benefits of the drug.